TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05275608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLCKD diet with replacing meals
Description: Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric mediterranean Diet
Description: Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
Study: NCT06177197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiomer
Description: Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day.
Study: NCT06309017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition specialist
Description: Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition shakes
Description: All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Surgery Immunonutrition shakes
Description: All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
Study: NCT06377696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear wearable device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear wearable device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05557851

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
Study: NCT05551000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental, comparator and control
Description: To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental, comparator and control
Description: To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group.
Study: NCT05396586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: N-back
Description: The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: N-back
Description: The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Span
Description: The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Span
Description: The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory
Description: The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory
Description: The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
Study: NCT05138822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: GSK3882347 will be administered on each dosing day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be administered on each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
Study: NCT05345015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy Transfer
Description: Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy Transfer
Description: Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation
Description: Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation
Description: Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
Study: NCT05411393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADL-enhanced program
Description: The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual home health rehabilitation therapy
Description: Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual home health rehabilitation therapy
Description: Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
Study: NCT05561127

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical ProTractX3 TTS DCB
Description: The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of Care Endoscopic Dilation
Study: NCT06236165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
Study: NCT05758376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Bridge
Description: Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
Study: NCT05937438

Intervention type: DRUG
Group type: OTHER
Intervention: Immune Checkpoint Inhibitors
Description: Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
Study: NCT06499896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTP-101-C
Description: MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTP-101-C
Description: MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
Study: NCT06036849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
Study: NCT06024356

Intervention type: DRUG
Intervention: Thymalfasin
Description: Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
Study: NCT06036849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
Study: NCT04844073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-186
Description: TAK-186 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-186
Description: TAK-186 IV infusion.
Study: NCT05495737

Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC Training
Description: Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
Study: NCT06447623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a kind of TKI inhibitor.
Study: NCT05495737

Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC Training
Description: Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment

Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC
Description: 3 sessions, completed over the course of 3-6 weeks in the participant's home

Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC
Description: 3 sessions, completed over the course of 3-6 weeks in the participant's home

Intervention type: BEHAVIORAL
Intervention: Treatment As Usual/TAU
Description: Research team will provide:~1. feedback about level of distress at time of screening~2. local referral for psychological care
Study: NCT06500130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Surface Gastric Mapping
Description: All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
Study: NCT06447623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 Inhibitor
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and Fulvestrant
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor and Fulvestrant
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study: NCT05425732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: 0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: 0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: 0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: 0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
Study: NCT04516538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination
Description: test for evaluating a person's cognitive functions and memory capacity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walk Test
Description: a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walk Test
Description: a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
Study: NCT06591026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: One digital helpline session that includes a structured motivational interviewing brief intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: One digital helpline session that includes a structured motivational interviewing brief intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: One digital helpline session that includes a structured motivational interviewing brief intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Description: One digital helpline session that includes a structured cognitive coping skills brief intervention.
Study: NCT04516538

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walk Test
Description: a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed up and go
Description: A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.